Skip to main content
    S

    Spyre Therapeutics Inc. (SYRE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $80.10
    +1.47 (+1.87%)

    Market Cap: $7.35B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    38%(15/39)
    Avg Surprise
    -467.79%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.83
    Range$-1.53 - $-0.66
    13 analysts
    EPS RevisionsNo revisions (7d)
    2
    8
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.73-14.0%
    60d ago$-0.73-14.0%
    30d ago$-0.81-2.1%
    7d ago$-0.83+0.7%
    Current$-0.83
    Revenue Consensus
    $0
    Range$0 - $0
    12 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.64
    Range$-2.58 - $-0.14
    13 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    12 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.64---
    Sep 26EST
    		-$-0.83---
    Jun 26
    Reported Aug 4
    		$-0.36$-0.71+49.30%Beat+26.5%
    Mar 26
    Reported May 5
    		$-0.74$-0.64-14.84%Miss-23.3%
    Dec 25
    Reported Feb 19
    		$-0.74$-0.80+7.50%Beat+8.6%
    Sep 25
    Reported Nov 4
    		$-0.15N/A+79.73%Beat+89.0%
    Jun 25
    Reported Aug 5
    		$-0.49$-0.71+30.99%Beat+43.0%
    Mar 25
    Reported May 8
    		$-0.60$-0.84+28.57%Beat+50.0%
    Dec 24
    Reported Feb 27
    		$-0.81$-0.94+14.22%Beat+80.0%
    Sep 24
    Reported Nov 7
    		$-1.36$-0.86-58.14%Miss+85.4%
    Jun 24
    Reported Aug 7
    		$-0.86$-0.91+5.49%Beat+98.5%
    Mar 24
    Reported May 9
    		$-1.20$-1.08-11.11%Miss+76.0%
    Dec 23
    Reported Feb 29
    		$-4.05$-0.78-419.23%Miss+19.0%
    Sep 23
    Reported Nov 9
    		$-9.34$-0.84-1011.90%Miss-96.6%
    Jun 23
    Reported Aug 11
    		$-56.75$-3.50-1521.43%Miss-740.7%
    Mar 23
    Reported May 11
    		$-5.00$-4.37-14.42%Miss+45.9%
    Dec 22
    Reported Mar 30
    		$-5.00$-0.23-2090.10%Miss+35.5%
    Sep 22
    Reported Dec 29
    		$-4.75$-5.87+19.08%Beat+38.7%
    Jun 22
    Reported Sep 28
    		$-6.75$-7.75+12.90%Beat-170.0%
    Mar 22
    Reported Jun 28
    		$-9.25$-0.34-2609.43%Miss-32.1%
    Dec 21
    Reported Mar 29
    		$-7.75$-7.63-1.57%Miss+11.4%
    Sep 21
    Reported Dec 29
    		$-7.75$-7.34-5.59%Miss-6.9%
    Jun 21
    Reported Sep 28
    		$-2.50$-4.30+41.86%Beat+75.0%
    Mar 21
    Reported Jun 28
    		$-7.00$-3.49-100.57%Miss+50.9%
    Dec 20
    Reported Mar 31
    		$-8.75$-0.34-2451.76%Miss+46.2%
    Sep 20
    Reported Nov 5
    		$-7.25$-9.97+27.28%Beat+56.1%
    Jun 20
    Reported Aug 10
    		$-10.00$-10.76+7.06%Beat+27.3%
    Mar 20
    Reported May 7
    		$-14.25$-16.41+13.16%Beat+3.4%
    Dec 19
    Reported Feb 24
    		$-16.25$-0.67-2325.37%Miss-4.8%
    Sep 19
    Reported Dec 29
    		$-16.50$-13.31-23.97%Miss-22.2%
    Jun 19
    Reported Aug 6
    		$-13.75$-12.08-13.82%Miss-19.6%
    Mar 19
    Reported May 7
    		$-14.75$-13.80-6.88%Miss-20.4%
    Dec 18
    Reported Mar 31
    		$-15.50$-0.37-4089.19%Miss-59.0%
    Sep 18
    Reported Dec 29
    		$-13.50$-10.80-25.00%Miss-12.5%
    Jun 18
    Reported Aug 9
    		$-11.50$-8.62-33.41%Miss+2.1%
    Mar 18
    Reported May 8
    		$-12.25$-11.51-6.43%Miss-4.3%
    Dec 17
    Reported Mar 31
    		$-9.75$-0.53-1739.62%Miss-1641.1%
    Sep 17
    Reported Dec 29
    		$-12.00$-13.77+12.85%Beat-
    Jun 17
    Reported Aug 9
    		$-11.75$-12.00+2.08%Beat-
    Mar 17
    Reported May 9
    		$-11.75$-11.70-0.43%Miss-
    Dec 16
    Reported Mar 31
    		$-0.56$-0.46-21.74%Miss-

    Key Metrics

    Valuation
    P/E Ratio-40.25EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-23.00%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio18.53xQuick Ratio18.53x
    Trading Statistics
    Beta3.11Avg Volume1.60M
    52-Week High$110.1752-Week Low$21.14

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$83.75
    SMA 20$86.11
    SMA 50$92.78
    SMA 200$69.85
    EMA 10$82.96
    EMA 20$85.47
    EMA 50$89.08
    EMA 200$72.86

    MACD

    Line: -3.12Signal: -2.64Hist: -0.48

    ADX

    ADX: 19.3+DI: 16.9-DI: 29.6

    Aroon & PSAR

    Aroon Up64.0
    Aroon Down80.0
    PSAR$89.69

    Bollinger Bands

    Upper Band$95.71
    Lower Band$76.51
    %B Position2229%(Upper)
    Band Width0.19

    RSI (14-Day)

    Neutral
    39.5

    Momentum Oscillators

    Stoch %K14.7
    Stoch %D26.1
    Williams %R-83.3
    ROC (10d)-10.9%
    Momentum-9.83
    CCI (20d)-115.5
    MFI (14d)24.2

    Volatility Measures

    ATR (14d)$5.08(6.3%)
    StdDev (20d)4.80
    Hist Vol68.6%(High)

    Volume Flow

    VWAP$79.49
    OBV43.5M
    AD Line17.3M
    CMF (20d)-0.172

    Volume Metrics

    Avg Vol (20d)1.6M
    Vol Ratio0.7x
    VWMA (20d)$85.33

    Pivot Points

    R3$85.90
    R2$84.18
    R1$81.40
    Pivot Point$79.68
    S1$76.90
    S2$75.18
    S3$72.40

    Advanced Oscillators

    TSI-19.30
    Ultimate Osc51.7
    KST-99.23

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$90.49M$0$0$0$0$0$0$0$1.04M$0
    Cost of Revenue$0$0$45.25M$0$0$0N/A$0$0$0$964,000$0
    Gross Profit$0$0$45.25M$0$0$0N/A$0$0$0$78,000$0
    Operating Expenses$41.64M$45.64M$57.17M$56.89M$41.94M$53.57M$61.25M$55.39M$44.15M$47.77M$45.91M$18.34M
    R&D$65.50M$60.41M$44.64M$45.25M$40.15M$41.62M$50.48M$44.74M$32.64M$34.93M$33.68M$24.36M
    SG&A$16.14M$15.23M$12.53M$11.64M$11.79M$11.94M$10.77M$10.65M$11.51M$12.85M$14.07M$8.58M
    Operating Income$-41,639,000$-45,641,000$-57,172,000$-56,888,000$-41,935,000$-53,567,000$-61,253,000$-55,392,000$-44,147,000$-47,774,000$-45,914,000$-18,337,000
    Interest Income$10.05M$7.00M$7.14M$5.38M$5.87M$6.49M$5.78M$5.18M$5.92M$4.43M$4.13M$1.25M
    Interest Expense$0$23.36M$5.36M$0$0$0$0$13.62M$0$0$17.27M$21.77M
    Income Before Tax$-36,200,000$-69,005,000$-62,530,000$-11,183,000$-36,717,000$-44,788,000$-56,295,000$-69,010,000$-38,837,000$-43,825,000$-63,180,000$-40,104,000
    Income Tax Expense$0$0$0$0$0$-15,000$1,000$18,000$0$32,000$0$3,000
    Net Income$-36,200,000$-69,005,000$-62,530,000$-11,183,000$-36,717,000$-44,773,000$-56,296,000$-69,028,000$-38,837,000$-43,857,000$-63,180,000$-40,107,000
    EBITDA$-49,346,000$-78,059,000$-71,754,000$-17,912,000$-44,604,000$-53,923,000$-64,490,000$-77,195,000$-48,318,000$-50,680,000$-69,012,000$-41,844,000
    EBIT$-46,253,000$-76,000,000$-69,669,000$-16,562,000$-42,591,000$-51,281,000$-62,071,000$-74,194,000$-44,757,000$-48,257,000$-67,306,000$-41,355,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SYRE

    News

    Fairmount Funds Management LLC Acquires 10,185,961 Shares of Spyre Therapeutics Inc (SYRE)

    Fairmount Funds Management LLC has acquired 10,185,961 shares of Spyre Therapeutics Inc (SYRE) for $80.85 per share...

    GuruFocus•10/15/26•Bullish

    UBS Initiates Spyre Therapeutics at Buy With $120 Price Target

    UBS has initiated coverage of Spyre Therapeutics (SYRE) with a "Buy" rating and a $120 price target. This aligns closely with the average analyst rating of "buy" and a mean price target of $121.57 for the company. Access...

    Yahoo Finance•10/12/26•Bullish

    UBS Initiates Spyre Therapeutics at Buy With $120 Price Target

    UBS has initiated coverage of Spyre Therapeutics with a Buy rating and a price target of $120. This rating suggests a positive outlook for the company's stock by the investment bank.

    Moomoo•10/12/26•Bullish

    SYRE Initiates Coverage by UBS -- Price Target Set at $120.00

    UBS has initiated coverage on Spyre Therapeutics (SYRE) with a 'Buy' rating and a price target of $120.00, despite the company's GF Score™ of 32/100...

    GuruFocus•10/12/26•Neutral

    UBS initiates Spyre stock with buy rating on IBD therapy potential

    UBS has initiated coverage on Spyre Therapeutics Inc. (NASDAQ:SYRE) with a Buy rating and a $120 price target, anticipating significant growth from its inflammatory bowel disease (IBD) therapy pipeline. The firm believes...

    Investing.com Nigeria•10/12/26•Bullish

    SYRE Valuation and Fair Value

    P/E
    -40.3x
    P/B
    7.1x
    See GNG's fair value

    SYRE Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -23.0%

    SYRE Competitors

    CompanyTicker
    HealthEquity IncHQY
    Ionis Pharmaceuticals IncIONS
    AptarGroup IncATR
    PACS Group, Inc.PACS
    Abivax SA American Depositary SharesABVX
    Merus BVMRUS
    Axsome Therapeutics IncAXSM
    Praxis Precision Medicines IncPRAX

    Sector: Healthcare

    SYRE Analyst Ratings

    Consensus
    Buy
    Analysts
    16
    Strong Buy
    0
    Buy
    15
    Hold
    1
    Sell
    0
    Strong Sell
    0

    SYRE Bull Case vs Bear Case

    Bull case

    • SYRE beat EPS estimates in 75.0% of its last 8 reported quarters.
    • 93.8% of SYRE's analyst ratings are Buy or Strong Buy.

    SYRE Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    17.2%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.83
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 8 down

    Frequently Asked Questions About SYRE

    Does SYRE pay dividends?

    Spyre Therapeutics Inc. (SYRE) does not currently pay a regular dividend.

    What is SYRE's market cap?

    Spyre Therapeutics Inc. (SYRE) has a market capitalization of $7.35B with a current stock price of $80.10.

    Related stocks

    Sector: Healthcare

    All stocks starting with S

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In